This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Magnesium glycerophosphate oral

Updated 2 Feb 2023 | Magnesium


Oral formulations of magnesium glycerophosphate.

Drugs List

  • MAG-4 97.2mg (4mmol) chewable tablet
  • MAGNAPHATE 97.2mg (4mmol) tablets
  • MAGNAPHOS 97.2mg (4mmol) chewable tablets sugar-free
  • magnesium glycerophosphate 97.2mg (4mmol) chewable tablet
  • magnesium glycerophosphate 97.2mg (4mmol) chewable tablets sugar-free
  • NEOMAG 97.2mg (4mmol) chewable tablet
  • YOURMAG 97.2mg (4mmol) chewable tablet
  • Therapeutic Indications



    Treatment of chronic magnesium deficiency or hypomagnesaemia.

    Treatment of hypomagnesaemia in adult patients due to the concomitant administration of loop and thiazide diuretics or other drugs.


    Dosage regimen should be adjusted according to individual serum total magnesium level.


    4mmol to 8mmol (1 to 2 tablets) three times a day.


    Children aged 12 to 18 years: 4mmol (1 tablet) three times a day.
    Children aged 4 to 12 years: 4mmol (1 tablet) twice a day.

    The following alternative dosing schedule may be suitable:
    Children aged 12 to 18 years: 4mmol to 8mmol three times a day (unlicensed).
    Children aged 1 month to 12 years: 0.2mmol/kg three times a day (unlicensed).


    Severe renal impairment

    Precautions and Warnings

    Children aged 1 month to 4 years
    Glucose-galactose malabsorption syndrome
    Hereditary fructose intolerance
    Renal impairment
    Small bowel resection

    Some formulations contain aspartame - caution in phenylketonuria
    Correct hypocalcaemia before or during treatment
    Presentations with sorbitol unsuitable in hereditary fructose intolerance
    Some formulations contain sucrose
    Advise patient not to take other medicines within 2 hours
    Correct hypokalaemia before or during treatment
    Monitor serum magnesium regularly

    Pregnancy and Lactation


    Use magnesium glycerophosphate with caution during pregnancy.

    The manufacturer recommends magnesium glycerophosphate is not used in pregnancy unless the benefits outweigh any potential risks.

    Available data following use in human pregnancy does not indicate an increased risk of teratogenic or developmental effects.


    Magnesium glycerophosphate is considered safe for use during breastfeeding.

    Manufacturers advise magnesium glycerophosphate may be use during breastfeeding.

    Magnesium glycerophosphate and its metabolites are excreted in human milk but at normal doses the effects are not considered to be clinically significant.

    Side Effects



    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: April 2020

    Reference Sources

    Summary of Product Characteristics: Magnesium 4mmol Chewable Tablets. Colonis Pharma Ltd. Revised November 2019.

    Summary of Product Characteristics: Neomag 4mmol Chewable Tablets. Neoceuticals Limited. Revised January 2017.

    NICE Evidence Services Available at: Last accessed: 16 April 2020

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.